Hydra and Cubist to collaborate on ion channel drugs
This article was originally published in Scrip
Executive Summary
Cubist Pharmaceuticals is to tap into Hydra Biosciences' research into ion channel compounds to treat pain. The two companies have signed a collaboration based on Hydra's work on compounds targeting the TRPA1 receptor.